cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.31113099.v1
title: A patent review of galectin-1 and galectin-3 inhibitors and their potential therapeutic applications (2022-present): an update

description: Galectin-1 (Gal-1) & Galectin-3 (Gal-3) are carbohydrate-binding proteins implicated in diverse pathological processes. These galectins have emerged as key therapeutic targets, with significant presence in drug discovery pipelines and clinical investigations. Their unique glycan-binding properties and immunomodulatory effects have prompted the development of inhibitors to modulate their function. This review presents a comprehensive summary of 19 small-molecule patents targeting Gal-1 and Gal-3, published from January 2022 to June 2025. A systematic search of Reaxys and WIPO databases yielded patents spanning modified monosaccharides & disaccharides, non-carbohydrate chemotypes and metal-coordinated complexes. The patent landscape is dominated by β-D-galactopyranose and thiodigalactoside scaffolds, with limited innovation and unresolved issues in selectivity, drug-likeness, and efficacy, highlighted by GB0139’s Phase II failure. Moreover, only a few patents provide structural evidence and strong in vitro/in vivo data, limiting confidence in their therapeutic outcome. By contrast, some diversification has emerged, including spirocyclic sugars, ruthenium-conjugates and non-carbohydrate ligands such as heterocycles and repurposed drugs. These highlight underexploited avenues with promise. Yet, robust biochemical data and structural proof of binding remain scarce. To move the field forward, future patents must diversify chemotypes, substantiate binding modes with crystallography or NMR, and demonstrate translation in relevant disease models.
DOI: 10.6084/m9.figshare.30561989.v1
title: A 96-week efficacy and safety of BIC/FTC/TAF in ART-naïve HIV-1 infected patients in China

description:  To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people living with HIV (PLWH). Retrospective cohort of ART-naïve PLWH initiating BIC/FTC/TAF between January 2020 and December 2022. Primary outcome was HIV-1 RNA &lt;50 copies/mL at week 96. Secondary outcomes included drug resistance and changes in CD4<sup>+</sup> T cell count, CD4<sup>+</sup>/CD8<sup>+</sup>, body weight, lipid profile, liver and renal function by week 96. We enrolled 228 patients; median age 32 years, 92.1% male, homosexual intercourse 57.0%. Virologic suppression did not differ by baseline HIV-1 RNA levels, CD4<sup>+</sup> T cell counts, or opportunistic infection (OI), and immune reconstitution was similarly consistent across subgroups. One patient developed V179E mutation. Median body mass index increased from 21.7 (20.0-23.7) to 23.1 (21.2-25.1) by week 48 and then stabilized. Lipid levels increased early and remained stable, liver function remained stable after week 48, and renal function showed a slight decline before stabilizing by week 48. BIC/FTC/TAF demonstrated strong efficacy in patients with high baseline HIV-1 RNA and OIs, with no patient developing drug-related resistance mutations and minimal impact on metabolism, liver and renal function, supporting its use in broader populations as a first-line regimen.
DOI: 10.6084/m9.figshare.31113105.v1
title: Blocking glycan production by targeting GALNT7 for prostate cancer therapy

description: Blocking glycan production by targeting GALNT7 for prostate cancer therapy
DOI: 10.6084/m9.figshare.31113105
title: Blocking glycan production by targeting GALNT7 for prostate cancer therapy

description: Blocking glycan production by targeting GALNT7 for prostate cancer therapy
DOI: 10.6084/m9.figshare.28139434
title: Prevalence of alcohol use and smoking in eating disorders: a systematic review and meta-analysis

description: The purpose of this study was a systematic review and meta-analysis of the prevalence of alcohol and smoking in eating disorders. The databases used in this study were PubMed, Scopus, and Web of Science. These databases were searched in English by December 2023. The sample size and event for alcohol use and smoking were extracted from each of the studies. Also, the subgroups were examined based on the types of eating disorders. The random-effects method was used to combine the results of the studies. The prevalence of alcohol use in eating disorders is equal to 27% (CI 23–32%; I2 = 99.6%). The prevalence of smoking in eating disorders is equal to 31% (CI 27–36%; I2 = 99.1%). The prevalence of alcohol use in anorexia nervosa, bulimia nervosa, and binge eating disorder was 26%, 390%, and 29% respectively. The prevalence of smoking in anorexia nervosa, bulimia nervosa, and binge eating disorder was 24%, 41%, and 35% respectively. Based on the findings, it was shown that the prevalence of alcohol use and smoking in eating disorders is high. Accordingly, this issue needs to be considered by health professionals and health policy to be used in activities related to prevention and treatment.
DOI: 10.6084/m9.figshare.28139434.v2
title: Prevalence of alcohol use and smoking in eating disorders: a systematic review and meta-analysis

description: The purpose of this study was a systematic review and meta-analysis of the prevalence of alcohol and smoking in eating disorders. The databases used in this study were PubMed, Scopus, and Web of Science. These databases were searched in English by December 2023. The sample size and event for alcohol use and smoking were extracted from each of the studies. Also, the subgroups were examined based on the types of eating disorders. The random-effects method was used to combine the results of the studies. The prevalence of alcohol use in eating disorders is equal to 27% (CI 23–32%; I2 = 99.6%). The prevalence of smoking in eating disorders is equal to 31% (CI 27–36%; I2 = 99.1%). The prevalence of alcohol use in anorexia nervosa, bulimia nervosa, and binge eating disorder was 26%, 390%, and 29% respectively. The prevalence of smoking in anorexia nervosa, bulimia nervosa, and binge eating disorder was 24%, 41%, and 35% respectively. Based on the findings, it was shown that the prevalence of alcohol use and smoking in eating disorders is high. Accordingly, this issue needs to be considered by health professionals and health policy to be used in activities related to prevention and treatment.
DOI: 10.6084/m9.figshare.30819969
title: Real-world analysis of medication adherence and cost of care for comorbid conditions in patients with early Alzheimer’s disease in the U.S.

description: To understand medication adherence and associated healthcare costs of patients with early Alzheimer’s disease (AD). This retrospective cohort study used the Axon Registry® linked with claims data to examine medication adherence of U.S. patients with early AD (mild cognitive impairment [MCI] and mild dementia due to AD) from 2015 to 2022. Medication adherence was quantified by the proportion of days covered (PDC) over a one-year follow-up, and adherence rate was defined at a PDC ≥ 80%. Patient comorbidities and healthcare costs were described. Of 333 patients included, 213 (64%) were female with a median (IQR) age 79 (72–83) years. Patients had a mean (SD) of 2.3 (2.1) comorbidities and took a mean (SD) of 3.0 (1.5) medications. Weighted-average PDC across medications was 74.4% with 7 out of 10 medication classes having a medication adherence rate lower than 60%. DPP-4 inhibitors had the highest medication adherence rate (66.67% of patients), and memantine had the lowest (39.13% of patients). Annual median (IQR) medical and pharmacy costs per-patient were $5,268 ($1,808–$14,651) and $658 ($187–$2,736), respectively. Patients with early AD had multiple comorbidities and took multiple medications. Suboptimal medication adherence and high healthcare costs were observed. This study looked at people in the early stage of their Alzheimer’s disease in the U.S. to understand the extent to which they were taking their medications. It also explored what other health problems those patients had, which medications they took, how often they took their medicine, and how much their healthcare costs were. Patients were chosen based on their scores on a cognitive assessment. Information about their health problems and medications was obtained from their health records. The study found that most patients had many other health issues in addition to Alzheimer’s disease. For these health issues, they were given many different medications. The study found that these patients did not take their medications as regularly as they were supposed to. The costs of medications and medical care were high for these patients. The study suggests that when prescribing medications for people with early Alzheimer’s disease, it is important to consider the comorbidities and manage the associated medication burden.
DOI: 10.6084/m9.figshare.30819969.v1
title: Real-world analysis of medication adherence and cost of care for comorbid conditions in patients with early Alzheimer’s disease in the U.S.

description: To understand medication adherence and associated healthcare costs of patients with early Alzheimer’s disease (AD). This retrospective cohort study used the Axon Registry® linked with claims data to examine medication adherence of U.S. patients with early AD (mild cognitive impairment [MCI] and mild dementia due to AD) from 2015 to 2022. Medication adherence was quantified by the proportion of days covered (PDC) over a one-year follow-up, and adherence rate was defined at a PDC ≥ 80%. Patient comorbidities and healthcare costs were described. Of 333 patients included, 213 (64%) were female with a median (IQR) age 79 (72–83) years. Patients had a mean (SD) of 2.3 (2.1) comorbidities and took a mean (SD) of 3.0 (1.5) medications. Weighted-average PDC across medications was 74.4% with 7 out of 10 medication classes having a medication adherence rate lower than 60%. DPP-4 inhibitors had the highest medication adherence rate (66.67% of patients), and memantine had the lowest (39.13% of patients). Annual median (IQR) medical and pharmacy costs per-patient were $5,268 ($1,808–$14,651) and $658 ($187–$2,736), respectively. Patients with early AD had multiple comorbidities and took multiple medications. Suboptimal medication adherence and high healthcare costs were observed. This study looked at people in the early stage of their Alzheimer’s disease in the U.S. to understand the extent to which they were taking their medications. It also explored what other health problems those patients had, which medications they took, how often they took their medicine, and how much their healthcare costs were. Patients were chosen based on their scores on a cognitive assessment. Information about their health problems and medications was obtained from their health records. The study found that most patients had many other health issues in addition to Alzheimer’s disease. For these health issues, they were given many different medications. The study found that these patients did not take their medications as regularly as they were supposed to. The costs of medications and medical care were high for these patients. The study suggests that when prescribing medications for people with early Alzheimer’s disease, it is important to consider the comorbidities and manage the associated medication burden.
DOI: 10.6084/m9.figshare.28139434.v1
title: Prevalence of alcohol use and smoking in eating disorders: a systematic review and meta-analysis

description: The purpose of this study was a systematic review and meta-analysis of the prevalence of alcohol and smoking in eating disorders. The databases used in this study were PubMed, Scopus, and Web of Science. These databases were searched in English by December 2023. The sample size and event for alcohol use and smoking were extracted from each of the studies. Also, the subgroups were examined based on the types of eating disorders. The random-effects method was used to combine the results of the studies. The prevalence of alcohol use in eating disorders is equal to 27% (CI 23–32%; I2 = 99.6%). The prevalence of smoking in eating disorders is equal to 31% (CI 27–36%; I2 = 99.1%). The prevalence of alcohol use in anorexia nervosa, bulimia nervosa, and binge eating disorder was 26%, 390%, and 29% respectively. The prevalence of smoking in anorexia nervosa, bulimia nervosa, and binge eating disorder was 24%, 41%, and 35% respectively. Based on the findings, it was shown that the prevalence of alcohol use and smoking in eating disorders is high. Accordingly, this issue needs to be considered by health professionals and health policy to be used in activities related to prevention and treatment.
DOI: 10.15468/dl.suybns
title: Occurrence Download

description: A dataset containing 27886 species occurrences available in GBIF matching the query:
{
 "and" : [
 "Continent is one of (Asia, Africa)",
 "TaxonKey is Sargassum"
 ]
}

 The dataset includes 27886 records from 149 constituent datasets; see https://api.gbif.org/v1/occurrence/download/0002519-260120142942310/datasets/export for details.
 
Data from some individual datasets included in this download may be licensed under less restrictive terms.
DOI: 10.6084/m9.figshare.29040021
title: Yiqi Wenyang decoction protects against the development of atherosclerosis by inhibiting vascular inflammation

description: Vascular inflammation is a key process in the pathogenesis of atherosclerosis, which is regulated by NF-κB pathway. Yiqi Wenyang decoction (YQWY), a Traditional Chinese medicine (TCM) formula, has anti-inflammatory properties and may inhibit this pathway, potentially offering anti-atherosclerotic effects. The purpose of this study is to investigate the effects of YQWY on atherosclerosis and the underlying mechanism. Materials and methods: ApoE<sup>−/−</sup> mice were fed a Western diet and administered with YQWY (low or high dose), atorvastatin, or vehicle for 13 weeks. The size of atherosclerotic plaques was assessed using ORO staining. Vascular inflammation was evaluated with IF or IHC staining. The mechanisms and signaling pathways underlying the effect of YQWY on vasculature were studied using transcriptomic analysis and were validated <i>in vitro</i> in endothelial cells and macrophages. YQWY attenuated atherosclerotic plaque development which was associated with reduced vascular inflammation as demonstrated by transcriptomic analysis of aorta. This was verified by reduced expression of proinflammatory chemokines, adhesion molecules, and inflammatory cytokines in aortas from YQWY-treated mice at both mRNA and protein levels. Mechanistically, YQWY suppressed NF-κB activation in endothelial cells and, to a lesser extent, macrophages possibly. YQWY protects against vascular inflammation and atherosclerosis by suppressing NF-κB pathway, suggesting the potential of YQWY and its active ingredients as novel anti-atherosclerotic therapeutics.
DOI: 10.6084/m9.figshare.29040021.v1
title: Yiqi Wenyang decoction protects against the development of atherosclerosis by inhibiting vascular inflammation

description: Vascular inflammation is a key process in the pathogenesis of atherosclerosis, which is regulated by NF-κB pathway. Yiqi Wenyang decoction (YQWY), a Traditional Chinese medicine (TCM) formula, has anti-inflammatory properties and may inhibit this pathway, potentially offering anti-atherosclerotic effects. The purpose of this study is to investigate the effects of YQWY on atherosclerosis and the underlying mechanism. Materials and methods: ApoE<sup>−/−</sup> mice were fed a Western diet and administered with YQWY (low or high dose), atorvastatin, or vehicle for 13 weeks. The size of atherosclerotic plaques was assessed using ORO staining. Vascular inflammation was evaluated with IF or IHC staining. The mechanisms and signaling pathways underlying the effect of YQWY on vasculature were studied using transcriptomic analysis and were validated <i>in vitro</i> in endothelial cells and macrophages. YQWY attenuated atherosclerotic plaque development which was associated with reduced vascular inflammation as demonstrated by transcriptomic analysis of aorta. This was verified by reduced expression of proinflammatory chemokines, adhesion molecules, and inflammatory cytokines in aortas from YQWY-treated mice at both mRNA and protein levels. Mechanistically, YQWY suppressed NF-κB activation in endothelial cells and, to a lesser extent, macrophages possibly. YQWY protects against vascular inflammation and atherosclerosis by suppressing NF-κB pathway, suggesting the potential of YQWY and its active ingredients as novel anti-atherosclerotic therapeutics.
DOI: 10.6084/m9.figshare.28944670
title: Tanshinone IIA reduces tubulointerstitial fibrosis by suppressing GSDMD-mediated pyroptosis

description: Tanshinone IIA (Tan IIA), a bioactive compound derived from the traditional Chinese herb <i>Salvia miltiorrhiza (Family Lamiaceae, Authority Bunge)</i>, is well-known for its protective effects in various kidney diseases. However, its role in obstructive nephropathy has not been thoroughly investigated. This study aimed to explore the protective effects of Tan IIA in a mouse model of unilateral ureteral obstruction (UUO) and to elucidate the cellular and molecular mechanisms underlying these effects. Gasdermin D (GSDMD) knockout mice and their wild-type (WT) littermates underwent UUO surgery, with Tan IIA treatment administered 24 h prior. Human proximal tubular cells (HK-2 cells) were treated with TGF-β1 to induce fibrosis (50 ng/mL for 24 h), followed by Tan IIA treatment (5 μM) for an additional 3 h. Tan IIA significantly reduced the expression of extracellular matrix (ECM) components, including collagen I, α-smooth muscle actin (α-SMA), vimentin and fibronectin, in UUO mice. Tan IIA attenuated GSDMD-mediated pyroptosis. However, in GSDMD knockout mice subjected to UUO, the protective effects of Tan IIA on ECM gene expression and collagen deposition in the tubular interstitium were reduced. <i>In vitro</i> studies showed that Tan IIA reduced GSDMD activation and fibronectin protein expression in HK-2 cells. Tan IIA may mitigate GSDMD-mediated pyroptosis in renal tubular epithelial cells (RTECs) and reduce kidney fibrosis, highlighting its potential as a therapeutic strategy to prevent the progression of kidney disease after ureteral obstruction.
DOI: 10.6084/m9.figshare.28944670.v1
title: Tanshinone IIA reduces tubulointerstitial fibrosis by suppressing GSDMD-mediated pyroptosis

description: Tanshinone IIA (Tan IIA), a bioactive compound derived from the traditional Chinese herb <i>Salvia miltiorrhiza (Family Lamiaceae, Authority Bunge)</i>, is well-known for its protective effects in various kidney diseases. However, its role in obstructive nephropathy has not been thoroughly investigated. This study aimed to explore the protective effects of Tan IIA in a mouse model of unilateral ureteral obstruction (UUO) and to elucidate the cellular and molecular mechanisms underlying these effects. Gasdermin D (GSDMD) knockout mice and their wild-type (WT) littermates underwent UUO surgery, with Tan IIA treatment administered 24 h prior. Human proximal tubular cells (HK-2 cells) were treated with TGF-β1 to induce fibrosis (50 ng/mL for 24 h), followed by Tan IIA treatment (5 μM) for an additional 3 h. Tan IIA significantly reduced the expression of extracellular matrix (ECM) components, including collagen I, α-smooth muscle actin (α-SMA), vimentin and fibronectin, in UUO mice. Tan IIA attenuated GSDMD-mediated pyroptosis. However, in GSDMD knockout mice subjected to UUO, the protective effects of Tan IIA on ECM gene expression and collagen deposition in the tubular interstitium were reduced. <i>In vitro</i> studies showed that Tan IIA reduced GSDMD activation and fibronectin protein expression in HK-2 cells. Tan IIA may mitigate GSDMD-mediated pyroptosis in renal tubular epithelial cells (RTECs) and reduce kidney fibrosis, highlighting its potential as a therapeutic strategy to prevent the progression of kidney disease after ureteral obstruction.
DOI: 10.6084/m9.figshare.30627898
title: Potential pharmacological quality control markers in the traditional Japanese medicine Hangeshashinto: identifying anti-inflammatory ingredients through a cell-based bioassay and multicomponent analysis

description: The traditional Japanese medicine Hangeshashinto (HST) is a multicompound drug used for stomatitis. The identification of HST’s active ingredients is essential for understanding its mechanism of action and establishing pharmacological quality control markers, but remains unclear due to its multicomponent drug. To systematically explore anti-inflammatory ingredients in HST using a combined approach involving a cell-based bioassay and multicomponent analysis, and to identify potential quality marker compounds. A cell-based bioassay modeling stomatitis was established using human oral keratinocytes (HOK), with interleukin (IL)-1β–induced prostaglandin E2 (PGE2) as an inflammatory indicator. The PGE2 inhibitory effects of quality-controlled 101 HST manufacturing lots were compared. Multicomponent analysis was performed on the 101 HST samples, correlating the intensity of 121 component peaks with the pharmacological activities. Ingredients with the highest correlation coefficients were validated for their PGE2 inhibitory effects. A total of 101 HST samples (30 µg/mL: approximately IC<sub>50</sub>) showed consistent inhibition of IL-1β–induced PGE2 production in HOK (41.33%–67.38% with 100% as IL-1β). Correlation analysis between PGE2 inhibitory activities and peak intensity of 121 components revealed the contribution of each ingredient to the pharmacological effect. Eight ingredients (glycycoumarin, neoglycyrol, [6]-shogaol, [8]-shogaol, [10]-shogaol, [6]-gingerol, [8]-gingerol, and [10]-gingerol) with the highest correlation coefficients (below −0.30) exhibited PGE2-inhibitory potential. The standardization of current quality control markers contributes to the stability of HST’s anti-inflammatory effects. The eight components discovered by this integrated analysis method may become novel quality control marker ingredients for further improving the pharmacological quality of HST.